Syros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) – Research analysts at Brookline Capital Management raised their Q1 2024 earnings estimates for Syros Pharmaceuticals in a research note issued to investors on Wednesday, March 27th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings per share of ($0.74) for the quarter, up from their prior forecast of ($0.94). The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($3.75) per share. Brookline Capital Management also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.77) EPS, Q3 2024 earnings at ($0.75) EPS, Q4 2024 earnings at ($0.99) EPS, FY2024 earnings at ($3.24) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at $1.68 EPS and FY2027 earnings at $6.91 EPS.

Separately, StockNews.com raised shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday.

Syros Pharmaceuticals Trading Down 8.4 %

Shares of NASDAQ:SYRS opened at $5.35 on Friday. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 1.09. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17. The company has a 50-day moving average price of $6.86 and a two-hundred day moving average price of $5.06.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Bain Capital Life Sciences Investors LLC raised its stake in shares of Syros Pharmaceuticals by 29.4% during the fourth quarter. Bain Capital Life Sciences Investors LLC now owns 2,749,808 shares of the company’s stock worth $21,421,000 after acquiring an additional 625,114 shares in the last quarter. Avidity Partners Management LP grew its holdings in shares of Syros Pharmaceuticals by 5.8% in the fourth quarter. Avidity Partners Management LP now owns 1,673,538 shares of the company’s stock worth $13,037,000 after purchasing an additional 92,396 shares during the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Syros Pharmaceuticals in the fourth quarter worth approximately $11,632,000. Point72 Asset Management L.P. bought a new position in shares of Syros Pharmaceuticals in the fourth quarter worth approximately $11,465,000. Finally, CHI Advisors LLC grew its holdings in shares of Syros Pharmaceuticals by 69.3% in the third quarter. CHI Advisors LLC now owns 1,299,359 shares of the company’s stock worth $5,119,000 after purchasing an additional 531,914 shares during the last quarter. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.